BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zenbexus (Iberdomide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zenbexus (Iberdomide)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05560399-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT05560399)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1\, Multiple Myeloma.\nStudy: A S
 tudy of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethaso
 ne for Relapsed/Refractory Multiple Myeloma\nEstimated primary completion:
  November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iberd
 omide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05560399
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465316-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT06465316)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1\, Multiple Myeloma.\nStudy: Tes
 ting Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or
  Refractory Multiple Myeloma\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06465316
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558319-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT05558319)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: NDM
 M Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs.
  Isa-V-Iberdomide\nEstimated primary completion: April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05558319
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05354557-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20270426
DTEND;VALUE=DATE:20270427
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT05354557)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Stu
 dy of Iberdomide in People With Multiple Myeloma Who Have Had an Autologou
 s Hematopoietic Stem Cell Transplant (AHCT)\nEstimated primary completion:
  26 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iberd
 omide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05354557
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727668-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT07727668)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1\, Multiple Myeloma.\nStudy: Ibe
 rdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis 
 for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refracto
 ry Multiple Myeloma (RRMM)\nEstimated primary completion: July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07727668
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06348108-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT06348108)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1\, Multiple Myeloma.\nStudy: Tal
 quetamab in Combination With Iberdomide and Dexamethasone for Relapsed or 
 Refractory Multiple Myeloma\nEstimated primary completion: 31 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06348108
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04776395-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT04776395)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide Alone or in Combination With Dexamethasone for the Treatment of In
 termediate- or High-Risk Smoldering Multiple Myeloma\nEstimated primary co
 mpletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04776395
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06215118-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT06215118)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1\, Multiple Myeloma.\nStudy: A S
 tudy to Learn About the Effects of the Combination of Elranatamab (PF-0686
 3135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myel
 oma (MagnetisMM-30)\nEstimated primary completion: 16 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06215118
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT04975997)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: Ope
 n-label Study Comparing Iberdomide\, Daratumumab and Dexamethasone (IberDd
 ) Versus Daratumumab\, Bortezomib\, and Dexamethasone (DVd) in Participant
 s With Relapsed or Refractory Multiple Myeloma (RRMM)\nEstimated primary c
 ompletion: 16 November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04975997
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04392037-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT04392037)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide Combined With Low-dose Cyclophosphamide and Dexamethasone\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/iberdomide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04392037
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107738-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT06107738)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Ce
 ll Transplant for Multiple Myeloma\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0610
 7738
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272826-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT05272826)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Stu
 dy of Iberdomide\, Bortezomib\, Dexamethasone With Isatuximab Added on Dem
 and for ND-NTE MM Patients\nEstimated primary completion: March 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05272826
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05583617-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT05583617)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: A
  Study Evaluating the Safety and Efficacy of Multiple Treatments in Partic
 ipants With Multiple Myeloma\nEstimated primary completion: 31 July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05583617
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434689-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT05434689)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: C
 OMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/iberdomide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05434689
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121843-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT06121843)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1\, Multiple Myeloma.\nStudy: A S
 tudy to Evaluate the Safety\, Effectiveness and Tolerable Dose of Arlocabt
 agene Autoleucel (BMS-986393) in Novel Combinations in Participants With R
 elapsed and/or Refractory Multiple Myeloma\nEstimated primary completion: 
 1 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iberdo
 mide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06121843
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06216158-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT06216158)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: Ibe
 rdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Ne
 wly Diagnosed Multiple Myeloma\nEstimated primary completion: December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06216158
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04884035-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT04884035)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1.\nStudy: Study of Safety and Ef
 ficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat L
 ymphoma\nEstimated primary completion: 1 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/iberdomide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04884035
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896228-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT05896228)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide\, Daratumumab\, Carfilzomib\, and Dexamethasone (Iber-KDd) in Pati
 ents With Relapsed/Refractory Multiple Myeloma\nEstimated primary completi
 on: 1 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibe
 rdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05896228
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827016-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT05827016)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: A S
 tudy to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance The
 rapy Following Autologous Stem Cell Transplant in Participants With Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 15 March 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05827016
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05169515-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT05169515)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1.\nStudy: A Study Evaluating the
  Safety\, Pharmacokinetics\, and Efficacy of Mosunetuzumab or Glofitamab i
 n Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-
 Hodgkin Lymphoma\nEstimated primary completion: 30 April 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05169515
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601100-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT07601100)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: I
 satuximab\, Iberdomide\, Bortezomib\, Dexamethasone in Transplant Ineligib
 le/Deferred Newly Diagnosed Myeloma\nEstimated primary completion: 1 July 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07601100
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07437963-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT07437963)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2.\nStudy: Testing the Addition
  of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back\
 , Not Responded to Treatment\, or Gotten Worse\nEstimated primary completi
 on: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/iberdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07437963
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05527340-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT05527340)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: Ibe
 rdomide-dexamethasone Alone or in Combination With Standard MM Treatment R
 egimens in Transplant Ineligible Newly Diagnosed Patients.\nEstimated prim
 ary completion: December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05527340
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06518551-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT06518551)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1\, Multiple Myeloma.\nStudy: ELE
 VATE-MM: Elotuzumab\, Iberdomide and Dexamethasone Post Idecabtagene Vicle
 ucel in Relapsed and Refractory Multiple Myeloma\nEstimated primary comple
 tion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/iberdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06518551
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04998786-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT04998786)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2\, Multiple Myeloma.\nStudy: A M
 ulti-center Open-label Phase 2 Study of Ixazomib\, Iberdomide and Dexameth
 asone in Elderly Patients With Multiple Myeloma at First Relapse."\nEstima
 ted primary completion: 1 January 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/iberdomide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04998786
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785415-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT06785415)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: E
 lotuzumab\, Daratumumab\, Iberdomide\, and Dexamethasone for the Treatment
  of Relapsed Multiple Myeloma\nEstimated primary completion: 1 April 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06785415
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762769-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Zenbexus (Iberdomide): Phase 2 readout est. (NCT06762769)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 2.\nStudy: Isatuximab and Iberdom
 ide as Immunotherapy for High Risk in Smouldering Myeloma\nEstimated prima
 ry completion: 1 November 2032. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/iberdomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06762769
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Zenbexus (Iberdomide): Phase 3 readout est. (NCT07624513)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 3\, Multiple Myeloma.\nStudy: D2 
 - Isa-Iber-VD Induction\, Followed by Risk & Response Adapted Consolidatio
 n & Maintenance\, in Transplant-Eligible NDMM\nEstimated primary completio
 n: 1 October 2033. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ib
 erdomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07624513
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Zenbexus (Iberdomide): Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1/2\, Multiple Myeloma.\nStudy: A
  Study to Assess Change in Disease Activity and Adverse Events (AE)s in Ad
 ult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-sp
 ecific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combi
 nations\nEstimated primary completion: December 2035. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/iberdomide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06896916-3209@assetmemo.bio
DTSTAMP:20261121T004013Z
DTSTART;VALUE=DATE:20360331
DTEND;VALUE=DATE:20360401
SUMMARY:Zenbexus (Iberdomide): Phase 1 readout est. (NCT06896916)
DESCRIPTION:Zenbexus (Iberdomide)\, phase 1\, Multiple Myeloma.\nStudy: Stu
 dy of Intravenously (IV) Infused Etentamig in Combination With an Oral Cer
 eblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events an
 d Change in Disease Activity in Adult Participants With Relapsed or Refrac
 tory Multiple Myeloma\nEstimated primary completion: March 2036. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/iberdomide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06896916
URL:https://assetmemo.bio/drug/iberdomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
